180 related articles for article (PubMed ID: 38701263)
1. Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
Feng J; Zhao Y; Zhai L; Zhou J
Medicine (Baltimore); 2024 May; 103(18):e38037. PubMed ID: 38701263
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Combination Therapy of Transarterial Chemoembolization and Apatinib for Unresectable Hepatocellular Carcinoma in the Chinese Population: A Meta-Analysis.
Wei Y; Liu J; Yan M; Zhao S; Long Y; Zhang W
Chemotherapy; 2019; 64(2):94-104. PubMed ID: 31569090
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
Zeng J; Lv L; Mei ZC
Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):688-697. PubMed ID: 27339594
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Duan R; Gong F; Wang Y; Huang C; Wu J; Hu L; Liu M; Qiu S; Lu L; Lin Y
World J Surg Oncol; 2023 Mar; 21(1):120. PubMed ID: 37004052
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.
Jiang N; Zhong B; Huang J; Li W; Zhang S; Zhu X; Ni C; Shen J
Front Immunol; 2023; 14():1205636. PubMed ID: 37583693
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Yang M; Yuan JQ; Bai M; Han GH
Mol Biol Rep; 2014 Oct; 41(10):6575-82. PubMed ID: 25091939
[TBL] [Abstract][Full Text] [Related]
9. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
[TBL] [Abstract][Full Text] [Related]
10. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis.
Xian F; Song XW; Bie J; Zhao CX; Zhang GJ; Xu GH
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):687-701. PubMed ID: 38305611
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
Liu JN; Li JJ; Yan S; Zhang GN; Yi PS
Front Oncol; 2023; 13():1074793. PubMed ID: 36910612
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
Zhang L; Hu P; Chen X; Bie P
PLoS One; 2014; 9(6):e100305. PubMed ID: 24945380
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
Ji J; Zhang Z; Hou Z; Qiu G; Mi S; Jin Z; Huang J
Clin Res Hepatol Gastroenterol; 2024 Apr; 48(4):102313. PubMed ID: 38453011
[TBL] [Abstract][Full Text] [Related]
15. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis.
Yang Y; Yu H; Qi L; Liu C; Feng Y; Qi J; Li J; Zhu Q
Int J Hyperthermia; 2022; 39(1):455-465. PubMed ID: 35271786
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis.
Cao DD; Xu HL; Liu L; Zheng YF; Gao SF; Xu XM; Ge W
Oncotarget; 2017 Jul; 8(27):44976-44993. PubMed ID: 28402958
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma: A systematic review and meta-analysis.
Song P; Hai Y; Ma W; Zhao L; Wang X; Xie Q; Li Y; Wu Z; Li Y; Li H
Medicine (Baltimore); 2018 May; 97(18):e0613. PubMed ID: 29718867
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Li D; Pang Y; Xu L; Xu X
J BUON; 2021; 26(4):1355-1364. PubMed ID: 34564992
[TBL] [Abstract][Full Text] [Related]
20. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Kong SY; Song JJ; Jin YQ; Deng MJ; Yan JX
Acta Clin Belg; 2023 Apr; 78(2):171-179. PubMed ID: 35587164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
